Last updated on November 2017

A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy


Brief description of study

A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic Therapy

Detailed Study Description

The target population for this study is women who are candidates to receive single agent fulvestrant endocrine therapy for metastatic, ER/PR+ and HER2 negative breast cancer. Such patients shall not have received prior treatment with chemotherapy in the locally advanced or metastatic disease setting and must have failed prior systemic therapy with a CDK inhibitor, and have tumors that are positive for heregulin (HRG) mRNA as assessed by RNA-ISH testing

Clinical Study Identifier: TX133435

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Columbus Regional Research Institute

Columbus Regional Research Institute
Columbus, GA USA
  Connect »